(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Scaling New Levels: Rock Climbing Spots On the planet - 2Step by step instructions to Pick the Ideal Authorize Internet Advertising Degree Program
- 3Current Chateaus: Advancement and Style
- 4UN chief calls on Yemen's Houthi rebels to free all UN detainees
- 5Air Force made critical errors during October 7 massacre, investigator says
- Conquering Language Boundaries: Individual Accounts of Multilingualism
- High-Suggested Broilers For Your Homes
- The cheap health insurance promoted by Trump officials has this catch
- Shah Capital pushes for Novavax sale, warns of proxy fight
- The ‘Stranger Things’ finale, explained: What happens to Vecna? And why was a key character’s fate left unknown?
- In Antarctica, photos show a remote area teeming with life amid growing risks from climate change
- The Most Paramount Crossroads in Olympic History
- Change Your Skincare: 10 Inventive Magnificence Gadgets
- Vietnam rethinks its flood strategy as climate change drives storms and devastation
